Wei Lv

Wei Lv

Auto-generated profile, based on publicly available information

Wei Lv

University of Illinois at Chicago, Chicago, IL

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
WLWei Lv
Wei Lv
BBBrian Budke
Brian Budke
MPMichal Pawlowski
Michal Pawlowski
PCPhilip P. Connell
Philip P. Connell
AKAlan P. Kozikowski
Alan P. Kozikowski
RAD51 is the central protein in homologous recombination (HR) DNA repair and represents a therapeutic target in oncology. Herein we report a novel class of RAD51 inhibitors that were identified by high throughput screening. In contrast to many previously reported RAD51 inhibitors, our lead compound 1 is capable of blocking RAD51-mediated D-loop formation (IC50 21.3 ± 7.8 μM) at concentrations that do not influence RAD51 binding to ssDNA. In human cells, 1 inhibits HR (IC50 13.1 ± 1.6 μM) without blocking RAD51’s ability to assemble into subnuclear foci at sites of DNA damage. We determined that the active constituent of 1 is actually an oxidized derivative (termed RI(dl)-1 or 8) of the original screening compound. Our SAR campaign also yielded RI(dl)-2 (hereafter termed 9h), which effectively blocks RAD51’s D-loop activity in biochemical systems (IC50 11.1 ± 1.3 μM) and inhibits HR activity in human cells (IC50 3.0 ± 1.8 μM).

1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
WLW. Lv
W. Lv
BBB. Budke
B. Budke
AKA.P. Kozikowski
A.P. Kozikowski
PCP.P. Connell
P.P. Connell